A randomized, open, Phase II comparison of the safety and efficacy of a reduced and re-escalated dose of sorafenib versus a reduced and maintained dose of sorafenib in patients with advanced hepatocellular carcinoma.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
Price : $35 *
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 13 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 25 Jul 2014 New trial record